NASDAQ:XERS Xeris Biopharma (XERS) Stock Price, News & Analysis $6.90 0.00 (0.00%) Closing price 06/17/2026 04:00 PM EasternExtended Trading$7.01 +0.11 (+1.65%) As of 07:26 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Xeris Biopharma Stock (NASDAQ:XERS) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Xeris Biopharma alerts:Sign Up Key Stats Today's Range$6.79▼$7.0650-Day Range$5.85▼$6.9352-Week Range$4.40▼$10.08Volume1.48 million shsAverage Volume1.51 million shsMarket Capitalization$1.19 billionP/E Ratio115.00Dividend YieldN/APrice Target$10.80Consensus RatingHold Company Overview Xeris Biopharma is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies for endocrine and orphan diseases. The company’s proprietary formulation platform is designed to enable liquid stability of drugs that traditionally require reconstitution before injection. By eliminating the need for on-site mixing and simplifying administration, Xeris aims to improve patient safety, adherence, and convenience in high-need therapeutic areas. The company’s flagship product, Gvoke, is a ready-to-use liquid glucagon autoinjector and prefilled syringe that has been approved by the U.S. Food and Drug Administration for the treatment of severe hypoglycemia in adults and pediatric patients with diabetes. Gvoke is the first and only ready-to-use glucagon rescue product, offering rapid emergency treatment without the time-consuming reconstitution steps required by traditional glucagon kits. In addition to Gvoke, Xeris is advancing a pipeline of liquid-stable therapies, including investigational rescue treatments for seizures and other acute conditions. Founded in 2008 and headquartered in Chicago, Illinois, Xeris Biopharma operates primarily in the United States while exploring international partnerships to expand the reach of its novel drug-delivery technologies. The company is led by President and Chief Executive Officer Paul Edick, whose leadership has guided Xeris from its early research stages through the commercialization of its first product. As Xeris continues to grow its portfolio, it aims to address unmet needs across a spectrum of endocrine and neurology indications.AI Generated. May Contain Errors. Read More Xeris Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreXERS MarketRank™: Xeris Biopharma scored higher than 61% of companies evaluated by MarketBeat, and ranked 386th out of 856 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.4 / 5Analyst RatingHold Consensus RatingXeris Biopharma has received a consensus rating of Hold. The company's average rating score is 2.43, and is based on no strong buy ratings, 4 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialXeris Biopharma has a consensus price target of $10.80, representing about 56.5% upside from its current price of $6.90.Amount of Analyst CoverageXeris Biopharma has only been the subject of 1 research reports in the past 90 days.Read more about Xeris Biopharma's stock forecast and price target. Earnings and Valuation1.9 / 5Proj. Earnings Growth183.33% Earnings GrowthEarnings for Xeris Biopharma are expected to grow by 183.33% in the coming year, from $0.12 to $0.34 per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Xeris Biopharma is 115.00, which means that it is trading at a more expensive P/E ratio than the market average P/E ratio of about 38.80.Price to Earnings Ratio vs. SectorThe P/E ratio of Xeris Biopharma is 115.00, which means that it is trading at a more expensive P/E ratio than the Medical sector average P/E ratio of about 24.58.Price to Book Value per Share RatioXeris Biopharma has a P/B Ratio of 86.25. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Xeris Biopharma's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted7.58% of the float of Xeris Biopharma has been sold short.Short Interest Ratio / Days to CoverXeris Biopharma has a short interest ratio ("days to cover") of 9.42.Change versus previous monthShort interest in Xeris Biopharma has recently increased by 1.21%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldXeris Biopharma does not currently pay a dividend.Dividend GrowthXeris Biopharma does not have a long track record of dividend growth. News and Social Media2.6 / 5News Sentiment0.22 News SentimentXeris Biopharma has a news sentiment score of 0.22. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.58 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Xeris Biopharma this week, compared to 3 articles on an average week.Search InterestOnly 4 people have searched for XERS on MarketBeat in the last 30 days. This is a decrease of -76% compared to the previous 30 days.MarketBeat Follows4 people have added Xeris Biopharma to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days. Company Ownership1.4 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Xeris Biopharma insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $766,733.00 in company stock.Percentage Held by Insiders4.35% of the stock of Xeris Biopharma is held by insiders.Percentage Held by Institutions42.75% of the stock of Xeris Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Xeris Biopharma's insider trading history. Receive XERS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Xeris Biopharma and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. XERS Stock News HeadlinesXeris Biopharma Holdings, Inc. (NASDAQ:XERS) Receives Consensus Rating of "Hold" from BrokeragesJune 13, 2026 | americanbankingnews.comJim Cramer Blesses a Caller’s Speculative Investment in Xeris BiopharmaJune 12, 2026 | insidermonkey.comBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going to hell." Ray Dalio agrees. The founder of Bridgewater Associates ($150 billion AUM) calls it a "debt death spiral." But there's a specific asset class and investment system that actually thrives when the dollar collapses.June 18 at 1:00 AM | Decentralized Masters (Ad)Xeris Biopharma Announces Notice of Allowance From U.S. Patent and Trademark Office for New Patent Covering KEVEYIS®June 11, 2026 | businesswire.comXeris to retire $23M of convertible notes through exchange agreementsJune 11, 2026 | seekingalpha.comXeris Biopharma Announces Private Exchange of Convertible NotesJune 11, 2026 | finance.yahoo.comXeris Biopharma (NASDAQ:XERS) Director Sells $91,350.00 in StockJune 6, 2026 | insidertrades.comXeris Biopharma (NASDAQ:XERS) Insider Beth Hecht Sells 16,667 SharesJune 3, 2026 | insidertrades.comSee More Headlines XERS Stock Analysis - Frequently Asked Questions How have XERS shares performed this year? Xeris Biopharma's stock was trading at $7.85 at the beginning of the year. Since then, XERS shares have decreased by 12.1% and is now trading at $6.90. How were Xeris Biopharma's earnings last quarter? Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) announced its earnings results on Thursday, May, 7th. The company reported $0.01 EPS for the quarter, topping the consensus estimate of $0.00 by $0.01. The firm earned $83.13 million during the quarter, compared to the consensus estimate of $79.83 million. Xeris Biopharma had a trailing twelve-month return on equity of 735.00% and a net margin of 3.81%. Read the conference call transcript. When did Xeris Biopharma IPO? Xeris Biopharma (XERS) raised $75 million in an IPO on Thursday, June 21st 2018. The company issued 5,000,000 shares at $14.00-$16.00 per share. Jefferies, Leerink Partners and RBC Capital Markets acted as the underwriters for the IPO and Mizuho Securities was co-manager. Who are Xeris Biopharma's major shareholders? Top institutional shareholders of Xeris Biopharma include Knott David M Jr (0.61%), Granahan Investment Management LLC (0.53%), Bank of America Corp DE (0.51%) and Sei Investments Co. (0.34%). Insiders that own company stock include John Patrick Shannon Jr, Paul R Edick, Kevin Mcculloch, Beth Hecht, John Johnson, Jeffrey W Sherman, Marla Persky, Barbara-Jean A Bormann-Kennedy, Dawn Halkuff and James Aloysius Brady. View institutional ownership trends. How do I buy shares of Xeris Biopharma? Shares of XERS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Xeris Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Xeris Biopharma investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE), CrowdStrike (CRWD). Company Calendar Last Earnings5/07/2026Today6/18/2026Next Earnings (Estimated)8/06/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Yellow Zone (3m+) 1-Year History Jun 25 Sep 25 Dec 25 Mar 26 Jun 26 XERS's financial health is in the Yellow zone, according to TradeSmith. XERS has been in this zone for over 3 months. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:XERS CIK1867096 Webwww.xerispharma.com Phone(844) 445-5704FaxN/AEmployees290Year FoundedN/APrice Target and Rating Average Price Target for Xeris Biopharma$10.80 High Price Target$18.00 Low Price Target$8.00 Potential Upside/Downside+56.5%Consensus RatingHold Rating Score (0-4)2.43 Research Coverage7 Analysts Profitability EPS (Trailing Twelve Months)$0.06 Trailing P/E Ratio115.00 Forward P/E Ratio57.50 P/E GrowthN/ANet Income$550 thousand Net Margins3.81% Pretax Margin3.81% Return on Equity735.00% Return on Assets3.24% Debt Debt-to-Equity Ratio17.00 Current Ratio2.12 Quick Ratio1.50 Sales & Book Value Annual Sales$291.85 million Price / Sales4.08 Cash Flow$0.10 per share Price / Cash Flow68.89 Book Value$0.08 per share Price / Book86.25Miscellaneous Outstanding Shares172,640,000Free Float165,132,000Market Cap$1.19 billion OptionableOptionable Beta0.78 Social Links Options Trading Made Easy - Download NowLearn the basics of options trading and how to use them to boost returns and manage risk with this free report from MarketBeat. Click the link below to get your free copy.Get This Free Report This page (NASDAQ:XERS) was last updated on 6/18/2026 by MarketBeat.com Staff. From Our PartnersBlackRock knows. Do you?BlackRock knows about it. JPMorgan knows. Bank of America knows. But most ordinary investors have never heard ...The Oxford Club | SponsoredBuffett's Final Warning: "The Dollar Is Going to Hell"On May 3rd, 2025, Warren Buffett looked at his shareholders for the last time and said: "The dollar is going t...Decentralized Masters | SponsoredBuy now or wait?SpaceX may be the biggest IPO in history, but according to Joel Litman - who called AMD before it rose as much...Altimetry | SponsoredYour book attachedBill Poulos is giving away his 'Safe Trade Options Formula' book for free - but only for a limited time throug...Profits Run | SponsoredSpaceX is offering you shares. Don't take them.SpaceX is reserving 30% of its IPO shares for retail investors through Robinhood, Fidelity, and Schwab. At a $...Behind the Markets | SponsoredThis is the worst news for stocks in 50 yearsGoldman Sachs and Morgan Stanley are issuing a rare warning: what's ahead for U.S. stocks could be the worst e...TradeSmith | SponsoredA 3M Oz. Historical Gold Resource And A Market That Hasn't Caught UpOne Canadian junior explorer controls a gold and copper system in British Columbia's Kootenay Golden Arc - a d...Wall Street Logic | SponsoredElon Is Quietly Doubling Down on This Bizarre AssetYahoo Finance reports this technology 'May Unlock $400 Trillion' - and Bloomberg calls it 'unavoidable.' Elon ...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xeris Biopharma Holdings, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xeris Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
